ERBB2 and breast carcinoma: Trastuzumab (TZ) is the first anti-HER2 monoclonal antibody and was approved in 1998 for breast cancer therapy both in monotherapy and adjuvant/neoadjuvant therapy with chemotherapy and/or surgery [10,11].